Steroid 5alpha-reductase inhibitors in androgen-dependent disorders.
Inhibition of the steroid 5alpha-reductases shows promise in the treatment of a number of androgen-dependent disorders, such as benign prostatic hyperplasia, male pattern baldness, and acne. The design of potent and isozyme-selective inhibitors has provided biologists and clinicians with important tools for elucidating complex androgen physiology, and has already resulted in the development of one marketed drug.
Department of Biochemistry, Merck Research Laboratories, Rahway, NJ 07065-0900, USA.
G S
GS
Harris
J W
JW
Kozarich
D058891:5-alpha Reductase Inhibitors; D000152:Acne Vulgaris / Q000188:drug therapy; D000505:Alopecia / Q000188:drug therapy; D000728:Androgens / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy
D058891:5-alpha Reductase Inhibitors; D000728:Androgens; D004791:Enzyme Inhibitors